凌科药业递交赴港IPO申请

Core Viewpoint - Lingke Pharmaceutical (Zhejiang) Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, aiming for a main board listing, with CITIC Securities (Hong Kong) Co., Ltd. and Jianyin International Financial Limited as joint sponsors [1] Company Overview - The company is a leading developer of innovative differentiated small molecule inhibitors for autoimmune and inflammatory diseases [1] - The clinical pipeline primarily focuses on the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway [1] Key Products - The core products include LNK01001, a highly selective second-generation JAK1 inhibitor with potential to become a best-in-class treatment [1] - LNK01004 is a potential first-in-class third-generation soft pan-JAK inhibitor targeting autoimmune and inflammatory diseases [1] - LNK01006 is an advanced, highly selective allosteric TYK2 inhibitor that can penetrate the central nervous system, targeting diseases related to the central nervous system [1] Innovation Platform - The company has established an innovative proprietary IsoNova protein degradation platform, utilizing robust single-molecule design to eliminate inactive isomers, thereby providing clearer and superior safety profiles [1]